stockrowCumberland Pharmaceuticals Inc.
CPIX Healthcare Drug Manufacturers Specialty & Generic
Cumberland Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, up 17.6% from fiscal 2024.
- Revenue
- −98.5%
- EPS
- −480.0%
- Free cash flow
- −82.8%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow CPIX
Alert me
Cumberland Pharmaceuticals Inc. (CPIX) EV/Sales
As of 5 November 2026, Cumberland Pharmaceuticals Inc. (CPIX) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from 0.4× (November 2024) to 4.5× (August 2026); the current reading is higher than 93% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.3× | 61.09% |
| FY2024 | 0.8× | 50.57% |
| FY2023 | 0.5× | (25.40%) |
| FY2022 | 0.7× | (55.73%) |
| FY2021 | 1.6× | 69.22% |
| FY2020 | 1.0× | (53.11%) |
| FY2019 | 2.1× | (22.80%) |
| FY2018 | 2.7× | 51.99% |
| FY2017 | 1.7× | 17.48% |
| FY2016 | 1.5× | 35.25% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.3× | 189.66% |
| Mar 2026 | 1.1× | (12.26%) |
| Dec 2025 | 1.3× | 28.65% |
| Sep 2025 | 1.0× | (3.95%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BGM BGM Group Ltd. compare | −0.1× |
| ZYBT Zhengye Biotechnology Holding Limited compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| ORGO Organogenesis compare | 0.3× |
| SCYX SCYNEXIS, Inc. compare | 0.5× |
| INCR InterCure Ltd. compare | 0.6× |
| CPIX Cumberland Pharmaceuticals Inc. | 2.6× |
| TLPH Talphera, Inc. compare | 156× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)